Nasal spray therapy shows promise in delaying Alzheimer's disease progression

Researchers at Texas A&M University are developing a nasal spray therapy aimed at delaying the progression of Alzheimer's disease. This new approach targets chronic inflammation in the brain using extracellular vesicles derived from human neural stem cells. In animal tests, the treatment reduced brain inflammation, amyloid-beta plaques, and Tau accumulation, while improving cognitive function and mood. The vesicles were shown to alter microglia gene expression, enhancing their protective role without increasing inflammation. A patent has been filed for this intranasal treatment, and further studies will assess its effectiveness at various stages of Alzheimer's. Successful results could potentially delay severe cognitive decline in humans by 10 to 15 years.